News

The U.S. Food and Drug Administration (FDA) has issued a warning letter to AstraZeneca for making false or misleading claims about Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate), its approved inhalation therapy for chronic obstructive pulmonary disease (COPD). According to the FDA, promotional material about Breztri distributed by AstraZeneca includes claims…

While smoking is a known risk factor for chronic obstructive pulmonary disease (COPD), heavy smokers can exhibit a series of respiratory symptoms without developing airflow blockage – one of the criteria to diagnose COPD – a study reports. The findings, which are based on the long-term follow-up of participants…

Breyna, a generic version of Symbicort (budesonide-formoterol), has been launched in the U.S. for eligible people with chronic obstructive pulmonary disease (COPD) and asthma. The inhaled medication — the first Symbicort generic to be approved by the U.S. Food and Drug Administration — will become immediately available…

Lower vitamin D levels in the blood are associated with an increased risk of chronic obstructive pulmonary disease (COPD), especially among smokers, according to a study looking at U.K. data. Adults with COPD who had lower vitamin D levels before their diagnosis were also at an increased mortality…

People who take inhaled corticosteroids for their chronic obstructive pulmonary disease (COPD) may be at lower risk for developing certain cardiovascular diseases, a review study has found. The study, “Inhaled Corticosteroids and Risk of Cardiovascular Disease in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Regression,”…

Many African Americans with clear symptoms of chronic obstructive pulmonary disease (COPD) don’t get a formal diagnosis because current diagnostic tools might not work as well for them, a study finds. Lung structure differences among African Americans that result in scores higher than the cutoff used to diagnose COPD…

Marpai, an artificial intelligence-powered administrator of employer health plans, is partnering with NuvoAir to provide virtual care for heart and lung conditions such as chronic obstructive pulmonary disease (COPD) to its health plan members and their families. “We are thrilled to offer NuvoAir to address the high-cost…

Verona Pharma has filed an application asking the U.S. Food and Drug Administration (FDA) to approve inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The regulatory submission “is a significant milestone towards our goal of bringing this potential first-in-class therapy to COPD patients…

People with chronic obstructive pulmonary disease (COPD) tend to experience worsening symptoms at times when levels of pollution in their community are higher, a new U.S. study indicates. “Our findings are consistent with a growing number of studies reporting adverse effects of community-level exposure to air pollution on respiratory…

People with diabetes or prediabetes are at an increased risk of developing chronic obstructive pulmonary disease (COPD), according to a recent study conducted in the U.K. A longer period of living with diabetes or a history of smoking further increases those odds. Among people who develop COPD, those who…